Stryker was granted FDA 510(k) clearance to market the OptaBlate bone tumor ablation system. The addition of the OptaBlate technology to Stryker’s Interventional Spine portfolio expands on its procedures for vertebral augmentation and radiofrequency ablation, and completes its portfolio of treatment options for metastatic vertebral body fractures.
Featuring four probes and Stryker’s microinfusion technology, OptaBlate allows physicians to customize their procedure and reduce ablation time by three minutes.
Specific key features of the system include:
Treatment of two vertebral body levels at once using a bipedicular approach
Quicker, more consistent ablation
Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring
“Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs,” said Greg Siller, Vice President and General Manager, Interventional Spine business, Stryker. “OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning.”
Stryker was granted FDA 510(k) clearance to market the OptaBlate bone tumor ablation system. The addition of the OptaBlate technology to Stryker's Interventional Spine portfolio expands on its procedures for vertebral augmentation and radiofrequency ablation, and completes its portfolio of treatment options for metastatic vertebral body...
Stryker was granted FDA 510(k) clearance to market the OptaBlate bone tumor ablation system. The addition of the OptaBlate technology to Stryker’s Interventional Spine portfolio expands on its procedures for vertebral augmentation and radiofrequency ablation, and completes its portfolio of treatment options for metastatic vertebral body fractures.
Featuring four probes and Stryker’s microinfusion technology, OptaBlate allows physicians to customize their procedure and reduce ablation time by three minutes.
Specific key features of the system include:
Treatment of two vertebral body levels at once using a bipedicular approach
Quicker, more consistent ablation
Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring
“Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs,” said Greg Siller, Vice President and General Manager, Interventional Spine business, Stryker. “OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning.”
Copy to clipboard 
